Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00258323 · ClinicalTrials.gov registry record · Phase 2

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

A Phase 2 study of Esophageal Cancer, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT00258323 is a Phase 2 study of Esophageal Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 80 participants, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00258323, a Phase 2 study of Esophageal Cancer, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Cisplatin and fluorouracil may also make tumor cells more sensitive to radiation therapy. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving radiation therapy together with combination therapy and gefitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving radiation therapy together with combination chemotherapy and gefitinib before and after surgery works in treating patients with advanced esophageal or gastroesophageal junction cancer.

Conditions Studied

Esophageal Cancer

Interventions

  • DRUG cisplatin
  • DRUG fluorouracil
  • PROCEDURE conventional surgery
  • RADIATION radiation therapy
  • DRUG Iressa

Study Locations (1)

Ohio

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2005-10
Est. Completion 2010-02
Phase Phase 2

Sponsor

Case Comprehensive Cancer Center

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00258323

The ClinicalTrials.gov registry entry for NCT00258323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 498-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.

NCT00258323 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00258323 about?

NCT00258323 is a clinical study titled "Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination ch...

What is the current status of trial NCT00258323?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-10. Estimated completion is 2010-02.

What conditions does trial NCT00258323 study?

This clinical trial studies the following conditions: Esophageal Cancer.

What interventions are being tested in trial NCT00258323?

The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION), Iressa (DRUG).

Who is sponsoring clinical trial NCT00258323?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00258323 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Esophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Esophageal Cancer

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.